Published in Radiat Res on June 17, 2014
Fresolimumab and Radiotherapy in Metastatic Breast Cancer | NCT01401062
Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer (2016) 1.08
Cancer vaccines. BMJ (2015) 1.07
Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park) (2015) 0.85
Immunobiology of radiotherapy: new paradigms. Radiat Res (2014) 0.84
Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Front Immunol (2015) 0.82
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. Front Oncol (2016) 0.77
Predictors of clinical response to immunotherapy with or without radiotherapy. J Radiat Oncol (2015) 0.77
Addressing the Symptoms or Fixing the Problem? Developing Countermeasures against Normal Tissue Radiation Injury. Radiat Res (2016) 0.75
Radiation meets immunotherapy - a perfect match in the era of combination therapy? Int J Radiat Biol (2015) 0.75
Progression of understanding for the role of Epstein-Barr virus and management of nasopharyngeal carcinoma. Cancer Metastasis Rev (2017) 0.75
Immunotherapy and radiation in glioblastoma. J Neurooncol (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 9.77
Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res (1992) 9.02
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol (2000) 5.45
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 5.21
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science (2011) 4.96
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med (2006) 4.84
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Tumor immunotherapy directed at PD-1. N Engl J Med (2012) 4.43
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 4.29
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res (2005) 4.23
Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2009) 3.90
The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev (2007) 3.33
Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol (2003) 3.18
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Systemic effects of local radiotherapy. Lancet Oncol (2009) 2.97
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res (2004) 2.91
A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol (2001) 2.87
Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol (2003) 2.87
Immune resistance orchestrated by the tumor microenvironment. Immunol Rev (2006) 2.83
Whole body irradiation; radiobiology or medicine? Br J Radiol (1953) 2.80
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol (2008) 2.61
The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res (2007) 2.54
Twelve immunotherapy drugs that could cure cancers. Immunol Rev (2008) 2.45
Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res (2007) 2.44
The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys (2012) 2.29
Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys (2005) 2.29
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev (2008) 2.08
A sense of danger from radiation. Radiat Res (2004) 2.02
Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest (1994) 2.01
Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol (2008) 1.93
Cytotoxic T lymphocytes form an antigen-independent ring junction. J Clin Invest (2004) 1.72
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res (1999) 1.60
Toll-like receptor agonists in cancer therapy. Immunotherapy (2009) 1.58
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest (2012) 1.55
The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res (2006) 1.51
Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res (2009) 1.51
Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. J Immunol (2002) 1.50
Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst (1979) 1.48
Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat Res (2006) 1.47
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res (2012) 1.46
Induction of adenocarcinomas of the colon in mice by weekly injections of 1,2-dimethylhydrazine. Cancer Res (1973) 1.37
Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med (1997) 1.35
Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res (2003) 1.32
Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res (2012) 1.31
TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res (2011) 1.30
CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res (2004) 1.25
The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol (2012) 1.24
The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev (2008) 1.22
Immunotherapy of cancer with 4-1BB. Mol Cancer Ther (2012) 1.19
Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys (2011) 1.17
Role of T lymphocytes in tumor response to radiotherapy. Front Oncol (2012) 1.12
GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol (2006) 1.08
Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res (2010) 1.06
Direct injection of immature dendritic cells into irradiated tumor induces efficient antitumor immunity. Int J Cancer (2004) 1.01
The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus. Cancer Res (2003) 0.99
Green fluorescent protein immunohistochemistry as a novel experimental tool for the detection of glioma cell invasion in vivo. Brain Pathol (2003) 0.99
Melanoma drug wins US approval. Nature (2011) 0.97
Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model. Radiat Res (2010) 0.91
The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime? Clin Cancer Res (2012) 0.84
Role of the crosstalk between CTLA-4 and NKG2D in the development of anti-CTLA-4 treatment strategies. Immunotherapy (2013) 0.76
Translational control in cancer. Nat Rev Cancer (2010) 4.59
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 4.29
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res (2005) 4.23
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol (2008) 2.61
A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell (2007) 2.44
Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys (2005) 2.29
eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol (2008) 2.26
Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol (2009) 1.99
Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med (2007) 1.79
Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol (2012) 1.76
Biologic comparison of partial breast irradiation protocols. Int J Radiat Oncol Biol Phys (2004) 1.71
Ethical, legal, and social issues related to genomics and cancer research: the impending crisis. J Am Coll Radiol (2005) 1.60
Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. J Clin Invest (2012) 1.55
Regulation of protein synthesis by ionizing radiation. Mol Cell Biol (2009) 1.52
The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res (2006) 1.51
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer. Clin Cancer Res (2012) 1.46
Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res (2010) 1.43
In regard to Kao et al.: concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials (Int J Radiat Oncol Biol Phys 2005;61:1045-1053). Int J Radiat Oncol Biol Phys (2005) 1.38
Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res (2012) 1.31
Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin Cancer Res (2009) 1.31
TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res (2011) 1.30
The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol (2012) 1.24
Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys (2012) 1.19
Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Cancer Res (2008) 1.15
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat (2010) 1.12
Role of T lymphocytes in tumor response to radiotherapy. Front Oncol (2012) 1.12
Prospective assessment of optimal individual position (prone versus supine) for breast radiotherapy: volumetric and dosimetric correlations in 100 patients. Int J Radiat Oncol Biol Phys (2012) 1.10
Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys (2006) 1.10
Select forms of tumor cell apoptosis induce dendritic cell maturation. J Leukoc Biol (2004) 1.08
Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.05
Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent. Cancer Lett (2012) 1.04
Low-dose radiation augments vasculogenesis signaling through HIF-1-dependent and -independent SDF-1 induction. Blood (2010) 1.03
Pharmacogenomics and breast cancer. Pharmacogenomics (2004) 1.02
Effects of chemoradiation on tumor-host interactions: the immunologic side. J Clin Oncol (2008) 1.00
ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.00
Prone hypofractionated whole-breast radiotherapy without a boost to the tumor bed: comparable toxicity of IMRT versus a 3D conformal technique. Int J Radiat Oncol Biol Phys (2011) 0.94
Radiotherapy effects on anti-tumor immunity: implications for cancer treatment. Front Oncol (2013) 0.93
Acquisition of stable inducible up-regulation of nuclear factor-kappaB by tumor necrosis factor exposure confers increased radiation resistance without increased transformation in breast cancer cells. Mol Cancer Res (2008) 0.92
Comparison of three-dimensional versus intensity-modulated radiotherapy techniques to treat breast and axillary level III and supraclavicular nodes in a prone versus supine position. Radiother Oncol (2011) 0.92
Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model. Radiat Res (2010) 0.91
Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology (2013) 0.90
Ischemic heart disease after breast cancer radiotherapy. N Engl J Med (2013) 0.89
Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Lett (2011) 0.89
Glioma-associated endothelial cells are chemoresistant to temozolomide. J Neurooncol (2009) 0.89
Atypical ezrin localization as a marker of locally advanced breast cancer. Breast Cancer Res Treat (2012) 0.89
Interfraction and intrafraction setup variability for prone breast radiation therapy. Int J Radiat Oncol Biol Phys (2009) 0.88
Coverage of axillary lymph nodes in supine vs. prone breast radiotherapy. Int J Radiat Oncol Biol Phys (2008) 0.88
Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors. Cancer Lett (2012) 0.87
The role of health system factors in delaying final diagnosis and treatment of breast cancer in Mexico City, Mexico. Breast (2011) 0.87
Results of surgical resection for progression of brain metastases previously treated by gamma knife radiosurgery. Neurosurgery (2006) 0.86
Prospective study of cone-beam computed tomography image-guided radiotherapy for prone accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys (2011) 0.86
Chemoradiation therapy versus chemotherapy alone for gastric cancer after R0 surgical resection: a meta-analysis of randomized trials. Oncology (2014) 0.85
Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress. Cancer Lett (2009) 0.85
Ionizing radiation modulates the exposure of the HUIV26 cryptic epitope within collagen type IV during angiogenesis. Int J Radiat Oncol Biol Phys (2002) 0.85
Vitronectin-αvβ3 integrin engagement directs hypoxia-resistant mTOR activity and sustained protein synthesis linked to invasion by breast cancer cells. Cancer Res (2013) 0.85
Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer. J Clin Oncol (2008) 0.85
Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature. Mol Cancer Ther (2010) 0.84
The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats. Biomaterials (2010) 0.84
Novel approaches to postoperative radiation therapy as part of breast-conserving therapy for early-stage breast cancer. Clin Breast Cancer (2003) 0.83
The vitamin-like dietary supplement para-aminobenzoic acid enhances the antitumor activity of ionizing radiation. Int J Radiat Oncol Biol Phys (2006) 0.83
Accelerated intensity-modulated radiotherapy to breast in prone position: dosimetric results. Int J Radiat Oncol Biol Phys (2007) 0.83
Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors. Int J Radiat Oncol Biol Phys (2008) 0.83
Prone accelerated partial breast irradiation after breast-conserving surgery: compliance to the dosimetry requirements of RTOG-0413. Int J Radiat Oncol Biol Phys (2012) 0.82
Radiation sensitivity of GL261 murine glioma model and enhanced radiation response by flavopiridol. Cell Cycle (2006) 0.82
Comparison of Acute and Late Toxicity of Two Regimens of 3- and 5-Week Concomitant Boost Prone IMRT to Standard 6-Week Breast Radiotherapy. Front Oncol (2012) 0.82
P7 antigen expression in human breast cancer. Clin Cancer Res (2003) 0.81
Mammography in developing countries: the risks associated with globalizing the experiences of the Western world. Nat Clin Pract Oncol (2008) 0.81
Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy. Int J Radiat Oncol Biol Phys (2012) 0.79
Re: Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst (2011) 0.78
Effect of particle size on the biodistribution of lipid nanocapsules: comparison between nuclear and fluorescence imaging and counting. Int J Pharm (2013) 0.78
Automated beam placement for breast radiotherapy using a support vector machine based algorithm. Med Phys (2012) 0.78
Hypofractionated radiation therapy for early stage breast cancer: outcomes, toxicities, and cost analysis. Breast J (2014) 0.78
Prone-breast radiotherapy: too early for conclusions: in regard to Chino et Al. (Int j radiat oncol biol phys 2008;70:916-920). Int J Radiat Oncol Biol Phys (2008) 0.77
Feasibility of accelerated whole-breast radiation in the treatment of patients with ductal carcinoma in situ of the breast. Clin Breast Cancer (2008) 0.77
Positioning during radiotherapy for breast cancer--reply. JAMA (2013) 0.77
Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomide. Front Oncol (2012) 0.76
Taxanes as radiosensitizers. Anticancer Drugs (2014) 0.76
Is classical stereotactic radiotherapy the optimal partner for immunotherapy? Oncology (Williston Park) (2015) 0.76
Loss of p27KIP1 expression in fully-staged node-negative breast cancer: association with lack of hormone receptors in T1a/b, but not T1c infiltrative ductal carcinoma. Anticancer Res (2011) 0.76
Decreasing temporal lobe dose with five-field intensity-modulated radiotherapy for treatment of pituitary macroadenomas. Int J Radiat Oncol Biol Phys (2009) 0.76
Breast cancer clinical and translational research: analogies and implications for prostate cancer. Rev Urol (2007) 0.75
Changes in breast radiotherapy: prone positioning and hypofractionation. Clin J Oncol Nurs (2013) 0.75
External beam partial-breast radiotherapy: crucial differences between NYU 00-23 and RTOG 0319: in regard to Vicini et al. (Int J Radiat Oncol Biol Phys 2005;63:1531-1537). Int J Radiat Oncol Biol Phys (2006) 0.75
Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals. Neurosurg Focus (2015) 0.75
Silvia Formenti on the Promise of Combining Radiotherapy and Immunotherapy to Treat Cancer. Oncology (Williston Park) (2016) 0.75
Emotional Intelligence and Burnout in Academic Radiation Oncology Chairs. J Healthc Manag (2017) 0.75